Feature

There are times where opportunities are not present in our environment, so sometimes it’s necessary to make them. Like the famous paleoanthropologist Donald Johanson said, “one must take initiative in life to achieve what he or she wants.” That is exactly what Laura Prestia, Ph.D., and her colleagues, Robert Sons, Ph.D., and Alan Alfano, Ph.D., did in 2016 when they started the Technology Transfer Ambassadors Program (TTAP).

Test your home for radon. I could think of at least 10 reasons why I didn’t want to. It was something else to add to the endless to-do list. The test kit would be expensive. If the test showed high levels, addressing the radon problem would be more expensive. In short, it was going to be a pain.

But as it happens, it wasn’t.

Picture this: a scientist works hard to make it through the interview process and accepts a job offer with NCI at Frederick. Filled with joy, she is eager to start right away. However, she has important steps ahead that can affect how soon her first day on the job will be. One is to obtain a PIV card.

HIV plays a direct role in causing blood cell cancers in rare instances, says a new study of HIV and tumor DNA. Scientists have long known that HIV contributes to several cancers by weakening the immune system’s ability to fend off cancer-causing infections. However, this latest study, published in Science Advances this week, is the first to demonstrate HIV as a cause.

The Biological Response Modifiers Program in Frederick had visitors. A group of well-regarded scientific experts arrived in 1991 to tour some of its laboratories and spaces. Learning about the program was only part of their goal, however. They were there to evaluate it.

The Frederick National Laboratory for Cancer Research (FNL) not only tackles some of the world’s greatest biomedical challenges but also serves as a shared national resource to enable high-quality research beyond its walls. One way FNL does this is through the Technical Services Program.

The Biological Response Modifiers Program had come into its own. Gone was any thought that this was a fleeting initiative. It was a robust mix of clinical and laboratory science at the forefront of immunotherapy, what was becoming the next major method for treating cancer. The program’s capabilities expanded in the second half of the 1980s, even as its clinical trials continued to reveal insights into biological agents for cancer treatment.

Pockets of the NCI at Frederick campus have popped with color the past few months. Staff working on-site may have noticed landscaped flowerbeds boasting arrays of annuals and files of ferns as they passed by larger buildings. The plants were installed thanks to the Campus Improvement Committee, a small group passionate about making a big impact.

Their study started to unravel the riddle of how cancers spread, demonstrating that tumors are comprised of different types of cells, or heterogeneous. Up to this point it was thought that cancer cells in a tumor were identical to each other. The work conducted by husband-and-wife Isaiah (Josh) Fidler, D.V.M., Ph.D., and Margaret Kripke, Ph.D., in Frederick would eventually be recognized as a landmark discovery that redefined the scientific understanding of tumor biology.

Sarah Hooper was hard at work in the intensive care unit at Frederick Memorial Hospital. The young nurse had joined the hospital staff in 1981—her first nursing position—and was spending her days monitoring, caring for, and helping patients in critical condition. All around her, they were struggling with respiratory problems, cardiac issues, and infections. But four beds were special. They were reserved for cancer patients participating in the Biological Response Modifiers Program.